Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Bioverativ Sobi" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Bioverativ Sobi for you to read. Along with our medical data and news we also list Bioverativ Sobi Clinical Trials, which are updated daily. BioPortfolio also has a large database of Bioverativ Sobi Companies for you to search.
Sobi is to buy Dova Pharmaceuticals for $915 million in a bid to grow Sobi’s hematology portfolio, with liver cancer and low blood platelet medication Doptelet at the centre. Doptelet remains on the lower end in terms of revenue, having launched in June 2018 and bringing in only $7.7 million last year and $3.5 million in the second quarter of 2019. Sobi believes the drug can fare better especial...
Svenska Sobi säjer en prioriteringsrätt till Astrazeneca för drygt 900 miljoner kronor.
Specialistläkemedelsbolaget Sobi köper amerikanska Dova Pharmaceuticals. Prislappen ligger på cirka 9 miljarder kronor.
The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, have extended their contract for the supply of Sobi’s Elocta (efmoroctocog alfa) until 31 December 2020. read more
Swedish Orphan Biovitrum AB (Sobi) sold AstraZeneca PLC a Priority Review Voucher for $95mm. Sobi gained the PRV when it acqu...
STOCKHOLM, Aug. 22, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 M. A PRV entitles the holder to FDA priority review of a single New …
Swedish Orphan Biovitrum AB (Sobi) has agreed to acquire US-based Dova Pharmaceuticals in a transaction valued up to $915m. Dova...Read More... The post Sobi to purchase Dova Pharmaceuticals in $915m deal appeared first on Pharmaceutical Technology.
Swedish Orphan Biovitrum, also known as Sobi, will acquire Dova Pharmaceuticals through a deal valued at up to $915 million. -More-
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
Shares of Dova Pharmaceuticals are up more than 38% in premarket trading after Sobi announced its intentions to acquire the company for $915 million.
In the past three years, Dova Pharmaceuticals has completed a company launch, gone public, and won its first drug approval. Now the biotech is in line to be acquired by Swedish Orphan Biovitrum (Sobi). According to deal terms announced Monday, Dova (NASDAQ: DOVA) stockholders will receive $27.50 per share up front, a 36 percent premium […]
The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals The post Sobi to buy Dova Pharmaceuticals in £915m deal appeared first on Pharmaceutical Business review.
The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals The post Sobi to buy Dova Pharmaceuticals in $915m deal appeared first on Pharmaceutical Business review.
AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead t...
Saniona, a Danish clinical-stage biotech company focused on rare diseases, named Rami Levin its new CEO. Levin was most recently president of the North America unit of Sobi, a rare disease biopharma headquartered in Sweden. He succeeds Jørgen Drejer, a Saniona founder, who will continue as chief scientific officer. Levin, who will be based in […]
A $2 billion impairment charge on Eloctate, acquired in Sanofi's 2018 Bioverativ buy, takes some shine off of a quarter boosted by surging Dupixent sales.
Rekryterar från Sobi.
Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent Value Right (CVR) for a total potential consideration of up to $915 million on a fully diluted basisAcquisition of Dova expected to enhance Sobi’s position as a leader in h...
Sobi to acquire Dova for $915m to broaden hematology franchise http://bit.ly/2oLdntV #ITP #hematology pic.twitter.com/YjG2t0qp70
Sobi to acquire Dova for $915m to broaden hematology franchise http://bit.ly/2oLdntV #ITP #hematology
Hopes to boost haematology franchise with lead drug Doptelet
Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy http://bit.ly/2Enj8CO pic.twitter.com/GfIMQv0o7j
Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy. http://bit.ly/2Enj8CO pic.twitter.com/Nw8mxcpWzn